Edwards Lifesciences (NYSE:EW)
- Number of Downgrades
- 24 (in the last 90 days)
- Consensus Rating
- Hold
- Rating Score
- 2.5
- Ratings Breakdown
- 12 Buy Ratings, 15 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $78.23 (20.2% Upside)
About Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.
Read More
Recent Analyst Ratings
